Merck (MRK) Change in Receivables (2009)

Merck (MRK) posted quarterly Change in Receivables of $14.0 million for Q4 2009, down 88.71% quarter-over-quarter from $124.0 million in Q3 2009.

Merck (MRK) Change in Receivables (2009) Analysis & Trends

Merck (MRK) has reported Change in Receivables for 1 consecutive years, with $14.0 million the latest figure, recorded in Q4 2009.

In Q4 2009, Change in Receivables changed N/A year-over-year to $14.0 million; the TTM figure through Dec 2009 stood at $1.4 billion (changed N/A YoY), while the FY2025 annual figure was $1.1 billion, up 346.72% from the prior year.
Change in Receivables retreated to $14.0 million in Q4 2009 per MRK's latest filing, from $124.0 million in the prior quarter.
Across five years, Change in Receivables topped out at $124.0 million in Q3 2009 and bottomed at $14.0 million in Q4 2009.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn	1.35 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn	1.37 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn	-
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn	-
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn	-
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn	1.09 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn	333.00 Mn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn	-
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn	-
10	Sanofi	55.07 Bn	47.69 Bn	10.79 Bn	-

Download Data